AbbVie Inc. (ABBV) Monday announced a higher response rate than placebo in the phase 2 trial of its investigational Lutikizumab 300 mg, every other week or weekly in patients with severe hidradenitis suppurativa or acne inversa, who had previously failed anti-TNF therapy.
Higher response rates were the primary endpoint. Based on these data, AbbVie will advance its clinical program of lutikizumab in hidradenitis suppurativa to Phase 3.
Hidradenitis suppurativa is a chronic, progressive, and irreversible inflammatory skin disease that can form lumps, abscesses, and scars under the arms, in the groin, and in other areas.
The company said all doses were generally well-tolerated.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.